Flather Nebivolol (n=1067) Aged 70 years new drug therapy for heart Chronic Heart Failure Beta-blockers in heart failure and concomitant atrial fibrillation NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Study Intervention and comparison Inclusion criteria Exclusion criteria , Mulder SENIORS Placebo (n=1061) clinical history of chronic heart failure with at least one of the following features: documented hospital admission within the previous 12 months with a discharge diagnosis of congestive heart failure or documented LVEF 35% within the previous 6 months failure in the 6 weeks prior to randomization a change in cardiovascular drug therapy in the 2 weeks prior to randomization heart failure due primarily to uncorrected valvular heart disease contraindication or previous intolerance to beta-blockers (e.g. heart rate < 60 bpm or systolic blood pressure <90 mm Hg) current use of beta-blockers significant hepatic or renal dysfunction cerebrovascular accidents within the previous 3 months being on a waiting list for percutaneous coronary intervention or cardiac surgery or other major medical conditions that may have reduced survival during the period of the study , Joglar US-HF Carvedilol (n=696) Placebo (n=398) Multicentre with varying treatment protocols. 